Emerald Announces Inclusion in the Industry's First ETF

VICTORIA, April 5, 2017 /CNW/ - Emerald Health Therapeutics Inc. (TSXV:EMH) ("Emerald" or the "Company") is pleased to announce its inclusion in the Horizon Medical Marijuana Life Sciences ETF (TSX:HMMJ) ("HMMJ ETF"), which began trading today and is the first ETF to offer direct exposure to North American-listed stocks that operate in the legal medical cannabis industry.

The HMMJ ETF seeks to replicate the performance of the North American Medical Marijuana Index of which we are one of the 16 constituents. Only stocks that meet minimum asset and liquidity thresholds are qualified for inclusion in the index, and no single stock may exceed 10% of the weight of the Index when rebalanced.

"Emerald's inclusion to the North American Medical Marijuana Index and HMMJ ETF represents an important milestone for our company and highlights the enormous efforts and successes of our team," said Avtar Dhillon, Executive Chairman. "Inclusion in the ETF should encourage broader participation in Emerald's shares, improving trading liquidity for our shareholders, as well as drive more funds to the cannabis sector on the whole, increasing awareness of the publicly traded companies and providing a more passive and diversified method for investors to participate in the truly unique cannabis investment opportunity."

This milestone compliments the company's breakout year in 2016, which earned Emerald a ranking of 3rd Place in the Clean Technology & Life Science sector of the 2017 TSX Venture 50® (see here), an award in recognition of being a top performer on the TSXV.

For more information on the constituents that are expected to make up the ETF's holdings, visit Horizon Exchange Traded Funds website here.

Join us on our journey of enhancing health through cannabis science.

For more information, explore our website and investor presentation at emeraldhealth.ca

Emerald Health Therapeutics Inc.

Emerald Health Therapeutics, Inc. operates primarily through Emerald Health Botanicals Inc. ("Botanicals"), a wholly owned subsidiary of the Company and a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (the "ACMPR"). Botanicals is authorized to cultivate and sell both dried medical cannabis flowers and medical cannabis oils in Canada. Botanicals currently operates an indoor cultivation facility in Victoria, British Columbia, and plans to construct a much larger purpose built hybrid greenhouse facility on 32 acres in metro Vancouver. Botanicals prides itself on being one of Canada's most medically focused licensed producers and on having one of the industry's most qualified management teams with respect to pharmaceutical drug discovery, development and distribution. Botanicals intends to capture unique niches in both the medical and future adult use cannabis markets through its proprietary strains, defensible intellectual property, and superb client experience.

"Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

SOURCE Emerald Health Therapeutics, Inc.

Copyright 2017 Canada NewsWire